Loading
ZT
ZyVersa Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$955.3k
ZyVersa Therapeutics, Inc.: what insiders have been doing
ZyVersa Therapeutics, Inc. has a thin disclosure history in our data (latest filing: 20 December 2022). New filings will appear here as soon as they are published. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
11
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.12
Analyst consensus
Income statement
EBITDA-US$25.3M
Net income-US$25M0.0% margin
Valuation
Beta0.86
Balance sheet & cash
Market capUS$955.3k
Free Cash Flow-US$5.1M
Profitability & ownership
ROA-34.5%
% insiders0.0%
% institutions5.1%
Last declaration on 20 December 2022
Declarations11 total
3,000 shares@ US$2.8815100.0% of flowCommon StockSEC:0001493152-22-035985:0
1,497,199 shares0Common StockSEC:0001493152-22-035808:0
1,377,598 shares0Common StockSEC:0001493152-22-035477:0
448,909 sharesCommon StockSEC:0001493152-22-035479:0
18,094 sharesCommon StockSEC:0001493152-22-035483:0
41,585 sharesCommon StockSEC:0001493152-22-035487:0
42,005 shares0Class A Common StockSEC:0001213900-22-011644:0
10,752 shares0Class A Common StockSEC:0001213900-22-011641:0
236,273 shares0Class A Common StockSEC:0001213900-22-011646:0
3,427 shares0Class B Common StockSEC:0001209191-22-016941:0
49,730 shares0Class B Common StockSEC:0001209191-22-007614:0
11 of 11 declarations
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for inflammatory and metabolic diseases. It aims to create therapies that target underlying disease mechanisms.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
